Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis
Crossref DOI link: https://doi.org/10.1007/s10067-016-3439-y
Published Online: 2016-10-05
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Windschall, D.
Horneff, G.
Funding for this research was provided by:
Pfizer Germany
Roche Germany
AbbVie Deutschland
License valid from 2016-10-05